Low expression of PP2A regulatory subunit B55α is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients.
about
The broken "Off" switch in cancer signaling: PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillanceProtein Phosphatase 2A as a Therapeutic Target in Acute Myeloid LeukemiaThe Basic Biology of PP2A in Hematologic Cells and MalignanciesPP2A: The Wolf in Sheep's Clothing?Inhibition of protein phosphatase 2A (PP2A) prevents Mcl-1 protein dephosphorylation at the Thr-163/Ser-159 phosphodegron, dramatically reducing expression in Mcl-1-amplified lymphoma cells.Role of AKT signaling in DNA repair and clinical response to cancer therapy.The protein phosphatase 2A regulatory subunit B55α is a modulator of signaling and microRNA expression in acute myeloid leukemia cells.Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer.Altered PPP2R2A and Cyclin D1 expression defines a subgroup of aggressive luminal-like breast cancer.Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.Phosphorylation of GSK3α/β correlates with activation of AKT and is prognostic for poor overall survival in acute myeloid leukemia patients.HEATR1 Negatively Regulates Akt to Help Sensitize Pancreatic Cancer Cells to Chemotherapy.Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.Novel B55α-PP2A mutations in AML promote AKT T308 phosphorylation and sensitivity to AKT inhibitor-induced growth arrest.Protein phosphatase 2A: a target for anticancer therapy.The Interplay between PP2A and microRNAs in Leukemia.All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase.RhoB loss induces Rac1-dependent mesenchymal cell invasion in lung cells through PP2A inhibition.Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation.Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors.Downregulation of PPP2R5E is a common event in acute myeloid leukemia that affects the oncogenic potential of leukemic cells.Distinct B subunits of PP2A regulate the NF-κB signalling pathway through dephosphorylation of IKKβ, IκBα and RelA.Phosphoproteomics Profiling of Nonsmall Cell Lung Cancer Cells Treated with a Novel Phosphatase Activator.RHOB expression controls the activity of serine/threonine protein phosphatase PP2A to modulate mesenchymal phenotype and invasion in non-small cell lung cancers.Role of MSC-derived galectin 3 in the AML microenvironment.Distinct protein signatures of acute myeloid leukemia bone marrow-derived stromal cells are prognostic for patient survival.
P2860
Q26739246-96BE48D8-002C-4EFC-B84D-7C431E6D4C1AQ26752430-12952E93-F7F2-4F7A-9781-E32B4589D608Q28088697-E30C0706-8C67-4499-BD55-E2C4AD664A00Q28088747-DD49A121-8B85-47D7-BE99-AF9B649C2A0EQ34070349-1E9C23B5-28C1-408B-A27C-AABD2B7EC7A5Q34193741-17CF881C-B406-49C5-8384-A5EB11A22E23Q34194198-7FF9AC78-E891-458E-9FE5-9F214F0C4BA5Q34260622-5D05A6DA-7E31-4BC4-9C58-90863E57B633Q34330600-0AB74BBD-42CF-42BB-ABEC-A07CBF8694DFQ35538100-1C917465-3C88-4E7A-AC43-9EA699857BD5Q36020877-57BF8CD2-3AE6-46D5-BA02-7D520FB0A456Q36324321-A17DD145-CCD4-4FA2-B1B3-2EA78AF49A11Q36535127-D9851DA8-2634-4BD4-AB5C-D01967C61EABQ36862768-3A26A559-6F56-47B8-83A3-1B873EE42BAAQ37641562-41A6AE1B-E4B3-4D0A-9060-FDB26F04865BQ38103646-D82852D4-7EBB-43EC-9E91-C7FA1B71EA08Q38370368-EF7A9F2E-94B7-43D9-84D4-A1CA85E6CF5DQ38617799-86741FA7-C94E-4B73-AB23-F77C19011D61Q38856262-39802A98-5AE5-4173-B755-189D4F2B8BEAQ39438493-5DA62023-965E-4EC1-B2BB-1BD549CDB5B0Q40859498-29B2ABC9-3BD8-4C36-8450-8D83A5173D3FQ42583764-D1143DCF-0CBD-47EE-84A6-ED9E4D70E3ABQ47400654-CF5A6823-9B49-4B69-B105-E70A450C9F68Q47618603-8E8CBBE0-5C85-4A82-8F98-96D8A3D3F348Q51456781-1B9E6AB8-8D60-4A3F-816D-B2492A48B3F3Q52588202-933AF512-A919-4349-B928-3922A5C30167Q52653312-B1BF95F0-65FB-48BD-BB74-04E39F0A8775
P2860
Low expression of PP2A regulatory subunit B55α is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Low expression of PP2A regulat ...... ute myeloid leukemia patients.
@ast
Low expression of PP2A regulat ...... ute myeloid leukemia patients.
@en
type
label
Low expression of PP2A regulat ...... ute myeloid leukemia patients.
@ast
Low expression of PP2A regulat ...... ute myeloid leukemia patients.
@en
prefLabel
Low expression of PP2A regulat ...... ute myeloid leukemia patients.
@ast
Low expression of PP2A regulat ...... ute myeloid leukemia patients.
@en
P2093
P2860
P356
P1433
P1476
Low expression of PP2A regulat ...... ute myeloid leukemia patients.
@en
P2093
G Borthakur
M Andreeff
M Konopleva
P P Ruvolo
S M Kornblau
V R Ruvolo
P2860
P2888
P304
P356
10.1038/LEU.2011.146
P577
2011-06-10T00:00:00Z